Lupitidine

Lupitidine (INN; lupitidine hydrochloride (USAN); development code SKF-93479) is a long-acting H₂ receptor antagonist^[1] developed by Smith, Kline & French and described as an antiulcerogenic that was never marketed.^[2] It was shown to inhibit nocturnal gastric acid secretion^[3] and, in experiments on rodents, produced diffuse neuroendocrine cell hyperplasia and an increase in multifocal glandular hyperplasia due to hypergastrinemia resulting from the pharmacological suppression of gastric acid secretion.^[4]

Lupitidine

Clinical data
ATC code	None
Identifiers
IUPAC name 2-[2-{{#parsoidfragment:1}}5-(2-Aminopropan-2-yl)furan-2-yl]methylsulfanyl]ethylamino]-5-[(6-methylpyridin-3-yl)methyl]-1H-pyrimidin-6-one
CAS Number	83903-06-4
PubChem CID	51671
ChemSpider	3577726
UNII	WF028DWK9N
KEGG	D04794
CompTox Dashboard (EPA)	DTXSID5043760
Chemical and physical data
Formula	C21H27N5O2S
Molar mass	413.54 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=NC=C(C=C1)CC2=CN=C(NC2=O)NCCSCC3=CC=C(O3)C(C)(C)N
InChI InChI=1S/C21H27N5O2S/c1-14-4-5-15(11-24-14)10-16-12-25-20(26-19(16)27)23-8-9-29-13-17-6-7-18(28-17)21(2,3)22/h4-7,11-12H,8-10,13,22H2,1-3H3,(H2,23,25,26,27) Key:CZTPLYMKHNEVHO-UHFFFAOYSA-N